FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-19.08%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$740M
AUM Growth
+$740M
(-11%)
Cap. Flow
+$58.9M
Cap. Flow
% of AUM
7.97%
Top 10 Holdings %
Top 10 Hldgs %
98.31%
Holding
16
New
3
Increased
–
Reduced
4
Closed
3
Top Buys
| 1 |
Lyell Immunopharma
LYEL
|
$216M |
| 2 |
Quantum-Si Incorporated
QSI
|
$54.7M |
| 3 |
Tempest Therapeutics
TPST
|
$2.13M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$85.1M |
| 2 |
ALX Oncology
ALXO
|
$58M |
| 3 |
Relay Therapeutics
RLAY
|
$57.9M |
| 4 |
Cytokinetics
CYTK
|
$6.67M |
| 5 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$3.68M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $225M | 30.43% | 9,671,643 | – | – |
|
|
2
Lyell Immunopharma
LYEL
$213M
| $216M | 29.16% | +13,282,181 | New | +$216M |
|
3
Pharvaris
PHVS
$1.39B
| $60.8M | 8.21% | 3,261,926 | – | – |
|
4
Aclaris Therapeutics
ACRS
$209M
| $59.7M | 8.07% | 3,399,034 | – | – |
|
|
5
Quantum-Si Incorporated
QSI
$227M
| $54.7M | 7.4% | +4,463,619 | New | +$54.7M |
|
6
Kura Oncology
KURA
$686M
| $38.6M | 5.21% | 1,849,947 | – | – |
|
7
Nurix Therapeutics
NRIX
$714M
| $32M | 4.32% | 1,205,798 -32,658 | -3% | -$866K |
|
|
8
Relay Therapeutics
RLAY
$619M
| $20.4M | 2.75% | 556,380 -1,583,000 | -74% | -$57.9M |
|
|
9
Cytokinetics
CYTK
$4.23B
| $10.8M | 1.46% | 545,101 -336,800 | -38% | -$6.67M |
|
10
Olema Pharmaceuticals
OLMA
$375M
| $9.57M | 1.29% | 342,030 -51,000 | -13% | -$1.43M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $7.79M | 1.05% | 1,787,094 | – | – |
|
|
DBTX
12
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $2.56M | 0.35% | 297,711 | – | – |
|
|
13
Tempest Therapeutics
TPST
$44M
| $2.13M | 0.29% | +190,212 | New | +$2.13M |
|
|
14
ALX Oncology
ALXO
$62.7M
| – | – | -785,945 | Closed | -$58M |
|
|
15
Keros Therapeutics
KROS
$618M
| – | – | -1,382,641 | Closed | -$85.1M |
|
|
PNT
16
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – | -350,000 | Closed | -$3.68M |
|